Every year, about 200 Americans get tularemia. Most recover, but some die. The US tularemia market report by MRFR shows that serological testing is the largest diagnosis method, but molecular diagnostics is the fastest‑growing. The market is $30.66 million and will hit $51.13 million by 2035, growing at 4.76% CAGR. Why the steady growth? Because the CDC tracks tularemia, and outbreaks still happen.

What's driving growth? Antibiotic therapy is the largest treatment segment, but supportive care is the fastest‑growing — as ICUs manage severe pneumonic cases. The US tularemia market analysis highlights that ulceroglandular tularemia is the most common infection type, but pneumonic tularemia is the fastest‑growing — driven by lawnmower and brush‑cutting exposures (inhaling bacteria from dead animals).

What's new? The US government is stockpiling antibiotics and diagnostics for biodefense. Also, a new vaccine candidate (ATI‑1701) is in preclinical development, funded by the Department of Defense.

The bottom line: tularemia is rare, but it's not extinct. If you live in a rural area, wear gloves when handling dead animals, and use insect repellent.